MarkWide Research - Global Market Intelligence Platform
Report Details
Historical Year
2020-2024
Base Year
2025
Forecast Period
2026-2036
Published Date
May 2026
No. of Pages
189 Pages
Delivery Format
PDF + Excel
Home›Industries›Healthcare›Diagnostics›Preeclampsia Diagnostics Market

Preeclampsia Diagnostics Market Size, Share, and Industry Trends Forecast 2026-2036

The Preeclampsia Diagnostics Market, valued at $1.42 Billion in 2026, is projected to expand to $3.01 Billion by 2035, registering a compound annual growth rate of 8.70%. Growth is pronounced in maternity hospitals and specialized prenatal care centers. The development and clinical validation of novel biomarker panels, which significantly improve risk stratification over traditional methods, is a key technological enabler. Demand is concentrating in the United States and parts of Europe, driven by updated clinical guidelines from professional societies and a focus on reducing maternal morbidity rates.

Preeclampsia Diagnostics Market Intelligence

Consolidation among large maternity hospital networks is restructuring procurement patterns for preeclampsia diagnostic tools, favoring suppliers with comprehensive portfolios. F. Hoffmann-La Roche Ltd leverages its extensive immunoassay platform to serve these large, integrated delivery networks. In contrast, Sera Prognostics specializes in novel biomarker-based tests for precise risk prediction, targeting high-risk obstetrics clinics. Siemens Healthineers AG competes with a portfolio that integrates both biochemical assays and advanced Doppler ultrasound devices.

Preeclampsia diagnostics encompass assays and devices used to identify and manage a hypertensive disorder of pregnancy. These tools often measure specific biomarkers, like the sFlt-1/PlGF ratio, to assess disease risk and enable timely clinical intervention. While blood pressure monitors form a foundational base, advanced biomarker panels represent the fastest-growing product segment due to superior predictive value. Immunoassay technology remains the standard for these biochemical assays, which are primarily utilized in diagnostic laboratories and maternity hospitals.

Regulatory bodies like the U.S. FDA and the European Medicines Agency (EMA) define the clinical validation requirements for new biomarker-based tests, influencing development timelines and costs. In China, the NMPA's approval process and GB standards for medical devices govern market access for both domestic and foreign manufacturers. The key decision for healthcare systems is how to integrate these predictive diagnostic tools into established prenatal screening protocols to improve outcomes.

Preeclampsia Diagnostics Market Size and Forecast

Market Dynamics

The central tension in the preeclampsia diagnostics market is the push for advanced biomarker adoption against the inertia of established clinical workflows. While novel tests offer superior predictive accuracy, their integration requires significant changes to prenatal screening protocols, physician training, and laboratory infrastructure.

Growth Catalysts

  • Novel Biomarker Panels:The clinical validation of biomarker ratios like sFlt-1/PlGF provides a significant improvement in risk stratification over traditional methods, enabling earlier and more targeted interventions in maternity hospitals.
  • Updated Clinical Guidelines:Professional societies, including the American College of Obstetricians and Gynecologists (ACOG), are incorporating biomarker testing into prenatal care recommendations, which accelerates adoption in the United States and Europe.
  • Maternal Health Initiatives:Government and public health focus on reducing maternal morbidity and mortality rates, particularly in developed nations, creates sustained demand for more precise diagnostic and prognostic tools in prenatal care centers.

Market Restraints

  • Reimbursement Hurdles:Inconsistent or absent reimbursement codes for new, higher-cost biomarker panels in many healthcare systems limits their accessibility and slows adoption, especially outside of major academic medical centers.
  • Assay Standardization Gaps:A lack of universal reference standards and cutoff values for key biomarkers across different manufacturers' immunoassay platforms creates clinical interpretation challenges for physicians.
  • Reliance on Traditional Methods:The continued use of inexpensive, foundational tools like blood pressure cuffs and urine dipsticks for initial screening in many regions delays the uptake of more advanced, predictive biochemical assays.

Strategic Opportunities

  • Emerging Market Expansion:Significant white space exists for diagnostic tools in large, populous countries like China and India, where rising healthcare expenditure and a focus on improving maternal-fetal outcomes present a major growth frontier.
  • Digital Health Integration:The convergence of biomarker data with electronic health records and AI-powered predictive algorithms offers an opportunity to create sophisticated, automated risk assessment platforms for obstetrics.
  • Point-of-Care Testing:Developing rapid, point-of-care assays for preeclampsia biomarkers would enable decentralized testing in outpatient clinics and labor and delivery units, drastically reducing turnaround times for critical decisions.

Industry Challenges

  • Clinical Workflow Integration:A primary operational hurdle is the difficulty of embedding new predictive test results into long-standing prenatal care pathways without disrupting existing patient management and physician decision-making processes.
  • Physician and Lab Training:A skills gap exists regarding the interpretation of complex biomarker ratios and the operation of advanced immunoassay analyzers, requiring significant investment in education for clinicians and laboratory staff.

Report Scope

MarkWide Research
AttributesDetails
Report TitlePreeclampsia Diagnostics Market
Market Size in 2026$1.42 Billion
Market Size in 2035$3.01 Billion
CAGR (2026 – 2036)8.7%
Historical Year2020-2024
Base Year2025
Forecast Period2026-2036
Segmentation
Product Type: Blood Pressure Monitors, Urine Protein Tests, Biochemical Assays, Doppler Ultrasound Devices, Biomarker Panels
Technology: Immunoassay, Enzyme-linked Immunosorbent Assay, Polymerase Chain Reaction, Chemiluminescence, Biosensors
Application: Early Detection, Risk Stratification, Disease Monitoring, Treatment Planning, Prenatal Screening
End User: Obstetrics Clinics, Diagnostic Laboratories, Maternity Hospitals, Prenatal Care Centers, Specialty Clinics
Companies CoveredF. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., PerkinElmer Inc., Siemens Healthineers AG, Abbott Laboratories, Sera Prognostics, Diabetomics, Inc., Metabolomic Diagnostics Ltd, QuidelOrtho Corporation, Others
Regions Covered
North America: US, Canada, Mexico
Europe: Germany, Italy, France, UK, Spain, Denmark, Sweden, Austria, Belgium, Finland, Turkey, Poland, Russia, Greece, Switzerland, Netherlands, Norway, Portugal, Rest of Europe
Asia Pacific: China, Japan, India, South Korea, Indonesia, Malaysia, Kazakhstan, Taiwan, Vietnam, Thailand, Philippines, Singapore, Australia, New Zealand, Rest of Asia Pacific
South America: Brazil, Argentina, Colombia, Chile, Peru, Rest of South America
Middle East & Africa: Saudi Arabia, UAE, Qatar, South Africa, Israel, Kuwait, Oman, North Africa, West Africa, Rest of MEA

Get the full picture before you read further.

Download a free sample with table of contents, companies, segments, and methodology.

Preeclampsia Diagnostics Market Strategic Shifts & Innovations

The convergence of advanced immunoassays with data analytics is defining the next generation of preeclampsia diagnostics. This shift moves the market from simple detection towards predictive risk modeling, enabling proactive rather than reactive clinical management of high-risk pregnancies.

Point-of-care testing platforms for biomarkers like PlGF are gaining traction. These devices provide rapid results directly within obstetrics clinics or maternity wards, bypassing the need for centralized laboratory processing. High-risk obstetrics clinics are adopting these systems to facilitate immediate clinical decisions, and this move toward decentralized analysis is electrifying the diagnostic workflow by shortening result turnaround from hours or days to minutes.

Europe's In Vitro Diagnostic Regulation (IVDR) is increasing the stringency of market access requirements. This framework mandates more extensive clinical evidence and rigorous post-market surveillance for all diagnostic tests, including established and novel preeclampsia assays. Manufacturers targeting the European Union must now generate more comprehensive performance and safety data, impacting development costs and timelines for biomarker-based products.

Risk-based screening algorithms are displacing uniform testing protocols for all pregnant individuals. This new model integrates multiple data points, including maternal history, Doppler ultrasound findings, and specific biomarker levels like the sFlt-1/PlGF ratio, to generate a personalized risk score. The approach is most visible in large, integrated hospital networks in the United States that are implementing value-based care initiatives.

Preeclampsia Diagnostics Market Segmentation

Preeclampsia Diagnostics Market Segment

The preeclampsia diagnostics market segmentation reveals the diverse tools and methods supporting maternal health management. Understanding these distinct categories helps stakeholders identify key areas of innovation and adoption. This segmentation provides clarity on where diagnostic advancements are most impactful across the care continuum.

Product Type:

Product type segmentation in preeclampsia diagnostics highlights the integration depth of various tools, from standalone monitoring devices to complex embedded biomarker systems.

  • Biomarker Panels:These advanced diagnostic tools analyze multiple biological markers, such as sFlt-1/PlGF ratios, to provide comprehensive risk stratification. Demand concentrates in large maternity hospitals and specialized prenatal care centers due to updated clinical guidelines.
  • Biochemical Assays:These tests measure specific substances in blood or urine, often utilizing immunoassay technology for precise quantification of markers like sFlt-1 and PlGF. Adoption is significant in diagnostic laboratories and integrated hospital networks for early risk assessment.
  • Blood Pressure Monitors:These foundational devices measure arterial pressure, forming the initial screening base in all prenatal care settings.
  • Urine Protein Tests:These simple assays detect proteinuria, serving as a rapid, cost-effective screening method in basic obstetrics clinics.
  • Doppler Ultrasound Devices:These imaging tools assess blood flow in uterine arteries, providing crucial information for placental function evaluation in high-risk obstetrics.

Volume placements concentrate in Blood Pressure Monitors; the faster expansion belongs to Biomarker Panels.

Technology:

Technology segmentation illustrates the diverse analytical platforms underpinning preeclampsia diagnostic capabilities, ranging from antigen-antibody reactions to nucleic acid amplification.

  • Immunoassay:This widely adopted technology detects and quantifies specific biomarkers using antigen-antibody reactions, forming the standard for biochemical assays in diagnostic laboratories. Adoption is significant in maternity hospitals for routine sFlt-1/PlGF ratio testing.
  • Chemiluminescence:This method enhances immunoassay sensitivity by producing light from a chemical reaction, enabling highly precise detection of low-concentration biomarkers. High-risk obstetrics clinics utilize this technology for improved predictive accuracy.
  • Enzyme-linked Immunosorbent Assay:ELISA techniques employ enzyme-linked antibodies for biomarker detection, offering a cost-effective solution for many diagnostic laboratories.
  • Polymerase Chain Reaction:PCR technology amplifies specific DNA or RNA sequences, finding niche applications in genetic predisposition studies for preeclampsia.
  • Biosensors:These devices integrate biological recognition elements with transducers, promising rapid, point-of-care detection of preeclampsia biomarkers in outpatient settings.

Immunoassay platforms currently dominate the installed base, while biosensors are gaining share fastest for decentralized testing.

Application:

Application segmentation outlines the specific clinical objectives addressed by preeclampsia diagnostic tools, from initial patient screening to ongoing disease management.

  • Early Detection:This application focuses on identifying preeclampsia markers before clinical symptoms manifest, enabling proactive intervention strategies in prenatal care centers. Advanced biomarker panels are central to this objective, improving maternal outcomes.
  • Risk Stratification:This involves categorizing pregnant individuals based on their probability of developing preeclampsia, guiding tailored surveillance and management plans. Maternity hospitals leverage sFlt-1/PlGF ratios for precise risk assessment.
  • Disease Monitoring:This application involves tracking disease progression and treatment response in diagnosed preeclampsia patients within specialty clinics.
  • Treatment Planning:Diagnostic insights inform clinical decisions regarding medication, timing of delivery, and other interventions in high-risk obstetrics.
  • Prenatal Screening:This broad application integrates various tests into routine pregnancy care to identify potential complications, including preeclampsia, across all end-user settings.

Prenatal screening represents the broadest application, but early detection and risk stratification are driving the most significant value expansion.

End User:

End-user segmentation delineates the primary healthcare facilities where preeclampsia diagnostics are deployed, reflecting varying levels of care and patient volume.

  • Maternity Hospitals:These large facilities provide comprehensive obstetric care, extensively utilizing advanced biomarker panels and Doppler ultrasound for both routine screening and high-risk case management. Consolidation among networks influences procurement patterns.
  • Diagnostic Laboratories:Centralized laboratories process a high volume of biochemical assays and immunoassay tests for preeclampsia biomarkers, supporting various clinical settings. Standardization gaps across platforms present interpretation challenges.
  • Obstetrics Clinics:These outpatient facilities focus on routine prenatal care, increasingly adopting point-of-care testing for rapid biomarker results.
  • Prenatal Care Centers:These centers offer foundational pregnancy monitoring, relying on blood pressure monitors and urine protein tests for initial assessments.
  • Specialty Clinics:These clinics manage complex or high-risk pregnancies, integrating advanced diagnostic tools for precise disease monitoring and intervention planning.

Maternity hospitals account for substantial device and assay procurement, while obstetrics clinics are experiencing rapid expansion in point-of-care adoption.

Preeclampsia Diagnostics Market Segmentation

Need this report tailored to your region?

Request specific countries, segments, or companies — tailored to your requirements.

Regional Outlook

Demand for preeclampsia diagnostics is concentrating in specific developed nations, driven by advanced clinical guidelines and initiatives to improve maternal health outcomes. These regions prioritize sophisticated biomarker panels for early risk assessment. Emerging economies like China and India also present significant growth potential.

United States

Demand for advanced preeclampsia diagnostics in the United States stems from updated clinical guidelines by the American College of Obstetricians and Gynecologists (ACOG) and a focus on reducing maternal morbidity rates. The U.S. FDA defines stringent clinical validation requirements for new biomarker-based tests, influencing development timelines. Large integrated hospital networks in cities like Boston are implementing value-based care initiatives, driving adoption of risk-based screening algorithms.

Germany

Germany's strong healthcare infrastructure and emphasis on precise diagnostics contribute to the demand for preeclampsia tools. The European Medicines Agency (EMA) and the In Vitro Diagnostic Regulation (IVDR) significantly impact market access and product development for diagnostic manufacturers. Research institutions in Munich focus on advanced biomarker development and their clinical integration into prenatal care protocols.

United Kingdom

The United Kingdom's national health initiatives to reduce maternal mortality rates and the adoption of risk-based screening algorithms spur the demand for predictive diagnostics. The EMA's IVDR also applies here, mandating extensive clinical evidence for diagnostic tests. London's specialized prenatal care centers are early adopters of point-of-care testing platforms for rapid biomarker analysis.

China

China's rising healthcare expenditure and a national focus on improving maternal-fetal outcomes present a major growth frontier for preeclampsia diagnostics. The NMPA's approval process and GB standards for medical devices govern market access for both domestic and foreign manufacturers. Major urban centers like Shanghai are seeing increased investment in advanced diagnostic laboratories and maternity hospitals.

India

India presents significant white space for diagnostic tools, driven by growing awareness of maternal health issues and expanding healthcare access. BIS standards and CDSCO regulations guide medical device and diagnostic approvals within the country. Healthcare providers in Delhi are expanding access to early detection and risk stratification tools, particularly in private sector maternity hospitals.

Preeclampsia Diagnostics Market Key Industry Players

Established producers occupy the standard tier, offering broad immunoassay platforms and foundational diagnostic tools. Emerging entrants pursue novel biomarker development and point-of-care solutions, aiming for enhanced predictive accuracy. This market structure features a mix of large, diversified healthcare technology firms and specialized diagnostics companies. Portfolio diversification, particularly through integrating advanced assays with existing device ecosystems, represents a dominant competitive move.

Within the comprehensive diagnostics tier, F. Hoffmann-La Roche Ltd, a Swiss-based pharmaceutical and diagnostics company, exemplifies leveraging extensive immunoassay platforms. Siemens Healthineers AG, a German medical technology firm, occupies a position integrating biochemical assays with advanced imaging devices. Sera Prognostics, an American biotechnology company, anchors the specialized segment, focusing on novel biomarker-based tests for precise risk prediction.

Leading Market Players
F. Hoffmann-La Roche Ltd
Thermo Fisher Scientific Inc.
PerkinElmer Inc.
Siemens Healthineers AG
Abbott Laboratories
Sera Prognostics
Diabetomics, Inc.
Metabolomic Diagnostics Ltd
QuidelOrtho Corporation
Others
Please note: The company list above is for reference and is subject to change. The final study will cover 15–20 leading companies in this market, and the final selection can be tailored to the client’s specific requirements.

Cost & Logistics Intelligence

Europe's In Vitro Diagnostic Regulation (IVDR) mandates extensive clinical evidence, gating qualified diagnostic supply and influencing premium-tier pricing for advanced biomarker tests.

Pricing Analysis

High-volume foundational diagnostics contrast sharply with high-margin advanced biomarker panels in the preeclampsia market. Value-based pricing emerges for advanced biomarker panels, reflecting superior predictive accuracy and clinical utility. Regulatory approval by bodies like the U.S. FDA and clinical validation drive premium pricing for novel biomarker assays. Cost compression in basic screening tools stems from widespread availability. Prenatal care centers exhibit high price sensitivity for basic diagnostics, while specialty clinics prioritize predictive accuracy.

Supply Chain Analysis

Dual-sourcing requirements for critical immunoassay reagents are becoming standard practice for large diagnostic laboratories. Key immunoassay components and specialized biochemicals source from Germany, the United States, and China. The supply chain relies on highly purified antibodies and specialized chemical reagents, creating single-source vulnerability for proprietary biomarker antibodies. Distribution primarily channels through medical device distributors to maternity hospitals and diagnostic laboratories.

Preeclampsia Diagnostics Market SWOT Analysis

Get the full picture before you read further.

Download a free sample with table of contents, companies, segments, and methodology.

Analyst Recommendations

The preeclampsia diagnostics market presents a significant cost-of-compliance story. Europe's IVDR creates a substantial barrier-to-entry moat, favoring established players capable of extensive clinical evidence generation and rigorous post-market surveillance.

For Market Incumbents: To counter the threat of emerging point-of-care solutions and assay standardization gaps, incumbent firms must prioritize portfolio diversification. Integrating advanced assays with existing device ecosystems strengthens their competitive position within integrated delivery networks. Investment in R&D for digital health integration, particularly AI-powered predictive algorithms, enhances risk assessment platforms. Consolidating immunoassay platforms also improves efficiency and reduces operational costs.

For New Entrants and Emerging Players: NMPA approval processes in China open a window for novel biomarker-based tests, particularly those addressing local clinical needs. New entrants should target emerging markets like China and India, where rising healthcare expenditure supports diagnostic tool adoption. Point-of-care testing in obstetrics clinics represents a penetrable segment due to demand for rapid results. A go-to-market angle focused on decentralized testing platforms offers a distinct competitive advantage.

For Investors and Strategic Acquirers: Consistent reimbursement for advanced biomarker panels in major European markets is the leading indicator that market barriers are receding. The preeclampsia diagnostics market demonstrates long-term viability, driven by sustained demand for precise diagnostic tools over the next decade. Acquisition targets should be specialized diagnostics companies possessing novel biomarker intellectual property or established point-of-care testing capabilities. Watch the adoption rate of sFlt-1/PlGF ratio testing in broader prenatal care settings for further market expansion.

Strategic InitiativeIndustry Significance
Clinical Validation ExpansionExtends the utility of novel biomarker panels, meeting stringent regulatory requirements from the U.S. FDA and EMA.
Digital Health IntegrationCreates AI-powered predictive algorithms, enhancing risk assessment for maternity hospitals.
Point-of-Care Assay DevelopmentEnables rapid, decentralized testing in obstetrics clinics, significantly reducing result turnaround times.
Emerging Market EntryCaptures growth in populous countries like China and India, addressing rising maternal health awareness.
Immunoassay Platform StandardizationAddresses assay standardization gaps, improving clinical interpretation for diagnostic laboratories and physicians.

Research Approach

Independent corroboration across clinical guidelines, regulatory filings, and academic literature underwrites the qualitative findings of this study. Primary interviews with obstetricians, laboratory directors, hospital procurement managers, and diagnostic manufacturers provided critical insights. Secondary validation utilized ACOG guidelines, U.S. FDA filings, and EMA submissions. A robust triangulation approach combined both bottom-up market sizing and top-down validation.

The forecast window was anchored to multiple historical reference periods, ensuring robust trend analysis across the analysis window. The analytical framework modeled segmentation across product type, technology, application, end-user, and regional regulatory frameworks. Compound annual growth rates derived from regression analysis of historical data and projected adoption rates. Key forecast inputs included biomarker panel adoption rates and updated clinical guideline implementation.

The model assumes a particular technology adoption path; alternative pathways for point-of-care testing would alter the outlook. Forecasts reflect assumptions regarding reimbursement policy stability and the pace of novel biomarker discovery. Deviation in regulatory approval timelines would shift the outlook materially.

Need Custom Data?

Can't find what you're looking for? Our analysts can build a custom report tailored to your exact requirements.

1,000+

Global Clients

150+

Countries Covered

65,000+

Reports Available

Frequently Asked Questions

Why Work With MWR

Trusted by 1,000+ businesses across 150+ countries for high-stakes market decisions.

Ready to access intelligence that moves business?

Browse Reports →

Trusted by Global Leaders

From Fortune-level organizations to global SMEs, we provide intelligence for high-stakes decisions.

Multi-Language Support

Research available in French, German, Spanish, Chinese, and more.

ISO & IAF Certified

Globally aligned quality standards ensuring methodological discipline and data integrity.

Competitive Relevance

Free inclusion of 3–4 additional companies of your choice in every report.

Customized Insights

Tailored intelligence for market entry, niche expansion, or competitive benchmarking.

Post-Sale Assistance

Dedicated coordination to help interpret findings and address queries post-delivery.

Cutting-Edge Methods

Structured data collection, advanced analytics, and expert validation for reliable forecasts.

Value for Investment

Credible, structured intelligence at a cost that makes strategic sense.

What Our Clients Say

"

My team needed the real numbers on AI spending for our Reinvention Services work. MarkWide delivered. No fluff, just a clear look at where the money is actually going. It saved us about three weeks of guesswork.

Accenture

"

We recently leaned on MarkWide Research for a deep dive into the evolving snacking habits within Southeast Asia. Their report on the premium biscuit segment was exceptionally detailed, providing us with the specific consumer sentiment data we needed to refine our regional flavor strategy. It wasn't just a data dump; the cultural nuances they captured helped us avoid several localization pitfalls.

Mondelez

Director of Global Consumer Insights

"

For a recent engagement in the automotive sector, we needed rigorous, independent verification of EV battery recycling capacities. MWR delivered a report that made our work easier. Their ability to segment the competitive landscape by chemical composition and regional throughput was exactly the kind of 'hard-to-find' intel that our team was looking for.

BCG

"

We were looking for a report on Xcelerator ecosystem's potential and got in touch with MarkWide's team through one of my old colleagues who worked with them in the past. Their research team was incredibly polite and were always available for us which was important for my team as this was a custom project. Their methodology for tracking industrial IoT adoption gave our R&D heads the clarity needed to prioritize our next-gen sensor development.

Siemens

Head of Industrial Digitalization

"

During a recent M&A project, we needed a fast, reliable breakdown of the Fintech landscape in Southeast Asia. MarkWide came through with a report that was actually readable and focused on the metrics that matter. It saved my team a good week of primary research, which, given our timelines, was a massive win.

KPMG

Advisory Partner

"

We tapped MarkWide Research for a deep dive into the ESG reporting software market. At Deloitte, our clients expect us to have the most current insights, and this report didn't disappoint. It provided a breakdown of the competitive field that was far more detailed than what we were expecting.

Deloitte

Lead Consultant, Sustainability Services

"

For our semiconductor division at Samsung, the supply chain forecast from MarkWide was incredibly useful. It provided a realistic outlook on raw material availability that helped us refine our production timelines. No fluff, just the data we needed to make a tough call.

Samsung

"

The value for our organization comes from three things: depth of research, specificity of segments and being easy to work with. As important as the first two are, the third can't be underestimated. MarkWide Research, maybe more than any other research vendor, wants to know what is top of mind for our team and what big questions we are grappling to answer. Their customer first approach and high value engagement model have given us great analysis and excellent value for money.

3M

"

I can share that it was a positive experience wherein MarkWide Research demonstrated flexibility to adapt to our needs and delivered an excellent report that fits all our requirements. Personally, I liked the timely follow up by the team and we will definitively reach out in case more research support is required.

VITO

Buy Now